IRCT20181229042160N4 IRCT 2023-12-24 Bagheiat-allah University of Medical Sciences Evaluation of antibacterial peptide eye drops EAPED Safety evaluation of eye drops containing antibacterial peptides in the treatment of infectious bacterial keratitis 2024-01-21 anticipated 10 Complete https://irct.ir/trial/74490 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment. 0 (exploratory trials) Bacterial keratitis. Intervention 1: Control group: Treatment using standard antibiotic eye drops (ceftazidime + vancomycin). Intervention 2: Treatment is done using standard antibiotic eye drops (ceftazidime + vancomycin) along with drops containing CM11 antibacterial peptide. For this purpose, eye drops containing 16 µg/ml peptide will be used. During the first week of treatment, patients use peptide drops at 4-hour intervals, and after that, at 6-hour intervals until the infection treatment. The peptide consists of 11 amino acids, synthesized by Morvarid Darou Company in pharmaceutical grade and formulated by Sina Darou Company. This peptide has broad-spectrum antibacterial activity. Yes - There is a plan to make this available What will be shared: All data can be presented after the study is done, keeping the identity of the people. When: Access starts 3 months after results are published. To whom: It is accessible to everyone. Conditions: There is no limit. Where to obtain: Using the email listed in the published article. How to obtain: By email and stating the reason for the request, which will be answered within a maximum of one week process. Comments: